Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: Implications of treatment duration and tumor volume

Head and Neck

Volumn 36, Issue 9, 2014, Pages 1349-1355

  Vargo, John A ^a   Heron, Dwight E ^a   Ferris, Robert L ^a   Rwigema, Jean Claude M ^a   Kalash, Ronny ^a   Wegner, Rodeny E ^a   Ohr, James ^a   Burton, Steven ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cetuximab; reirradiation head and neck; stereotactic body radiation therapy (SBRT); treatment time; tumor volume

Indexed keywords

CETUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BONE NECROSIS; CANCER CONTROL; CANCER RECURRENCE; DYSGEUSIA; DYSPHAGIA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; RADIATION HAZARD; RECURRENCE FREE SURVIVAL; SKIN TOXICITY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME; XEROSTOMIA; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PATIENT SELECTION; RADIOSURGERY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; RADIOSURGERY; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84906087277     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23462     Document Type: Article

References (22)

1. Siegal R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Choong N, Vokes E,. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 2008; 58: 32-53.
3. Chen AM, Phillips TL, Lee NY,. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys 2011; 81: 1211-1219.
4. Rwigema JC, Heron DE, Ferris RL, et al. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol 2010; 33: 286-293.
5. Comet B, Kramar A, Faivre-Pierret M, et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012; 84: 203-209.
6. Siddiqui F, Patel M, Khan M, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009; 74: 1047-1053.
7. Unger KR, Lominska CE, Deeken JF, et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1411-1419.
8. Kodani N, Yamazaki H, Tsubokura T, et al. Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res 2011; 52: 24-31.
9. Roh KW, Jang JS, Kim MS, et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1348-1355.
10. Cengiz M, Özyiǧit G, Yazici G, et al. Salvage reirradiation with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011; 81: 104-109.
11. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009; 75: 1493-1500.
12. Withers HR, Peters LJ,. Transmutability of dose and time. Commentary on the first report of RTOG 90003 (K. K. Fu et al.) Int J Radiat Onco Biol Phys 2000; 48: 1-2.
13. Platek ME, McCloskey SA, Cruz M, et al. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck 2013; 35: 684-688.
14. Rwigema JC, Heron DE, Ferris RL, et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol 2011; 34: 372-379.
15. Vargo JA, Wegner RE, Heron DE, et al. Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. Head Neck 2012; 34: 1153-1161.
16. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL,. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol 2011; 34: 165-172.
17. Fowler J, King CR,. Don't squeeze hypofractionated schedules into too-short overall times. Int J Radiat Oncol Biol Phys 2009; 75: 323-325.
18. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr,. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 1043-1048.
19. Ong CL, Palma D, Verbakel WF, Slotman BJ, Senan S,. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiather Oncol 2010; 97: 431-436.
20. Dunlap NE, Larner JM, Read PW, et al. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010; 140: 583-589.
21. Wada H, Takai Y, Nemoto K, Yamada S,. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004; 58: 1114-1120.
22. Sawrie SM, Fiveash JB, Caudell JJ,. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control 2010; 17: 111-119.